DNA to guard Dubbo stores

Oct. 9, 2012, 4:30 a.m.

IN A first for regional NSW, criminals will no longer feel safe as new DNA technology helps authorities put them behind bars.

The innovative technology known as the DNA Guardian is set to revolutionise crime prevention in Dubbo, after it was installed at Club Dubbo and convenience store Lucky 7 yesterday.

It is the first time this kind of technology has been implemented in regional NSW.

DNA Security Solutions, based in Adelaide, specialises in criminal marking systems. When a DNA Guardian unit is installed within a premises, it can immediately pick up on when a crime occurs.

Business development worker Jeffre Murray explained how sterile water could help identify a criminal with one simple spray.

When a DNA Guardian unit is installed in a pub or shop, crime can easily be picked up. The unit is triggered when a theft occurs, and sprays the criminal with sterile water, marking them as they leave the premises, Mr Murray said.

DNA workers and business owners, he said, would immediately receive a text message informing them of the crime. Once it is brought to their attention, they can then view CCTV footage, get a clearer idea of what the criminal looks like, and help police track them down.

Once police are notified, they only have to shine a forensic blue light on criminals to match their DNA with what was found at the scene of the crime, and formally identify them as the responsible party, Mr Murray said.

He said he had notified members of Dubbo Police before his arrival to Dubbo, who were quite impressed with the DNA equipment.

Here is the original post:
DNA to guard Dubbo stores

Posted in DNA

Student Cameron Kim, Working to Reprogram Cells

By Nonie Arora

Meet Cameron Kim a Pratt Engineering student working on synthetic biology who also officiates for the Duke Quidditch team. Originally from Brandon, Florida, Cameron became interested in molecular biology and engineering in high school.

Kim Observing His DNA Gel Credit: Cameron Kim

I see most people identify biomedical engineering as biomechanics, neural engineering, and electrophysiology, he says, but theres really this other side growing quicker and quicker, which is using the tools of molecular biology to control how we as humans function and interact with the environment.

InDr. Charles Gersbachs lab, he has been working to create artificial transcription factors. Being able to control gene expression through transcriptional factors is vital to modulate cell behavior and human functions, Kim says.

Kim drew an analogy between a transcription factor and a light switch dimmer, saying that transcription factors allow for a range when turning on and off specific genes. He says that artificial transcription factors would allow him to influence a cells own genome without having to add extra copies of a gene. The goal is to develop a tool to reprogram cells that his lab can use to study muscle development and to hopefully repair muscles. His lab is looking at different ways to develop therapies for Duchenne muscular dystrophy.

Kim thinks that engineering design principles that he has learned through his Pratt coursework are really important to his project. When I explain my research to a lot of people, they think Im just doing molecular biology, he says, but by knowing the parts and understanding my materials, I can design biological molecules and tools do what I want them to do. While we may traditionally associate engineers observing factors like the terrain or landscape to build a bridge, he looks at factors like energy barriers and cell functions to apply design principles to molecular biology.

Kim Presenting at the Howard Hughes Research Symposium Credit: Cameron Kim

Research is full of challenges, and Kims projects have been no exception. He says it has been challenging to develop his tool. While it looks great in one test, it does not work with another one. He is still investigating whether he should be looking for other factors to control or whether the challenges are due to biological limits.

When asked what advice he would give to other undergrads excited about delving into research, Kim said to recognize that youre not going to know everything and even brightest minds in the field dont know everything, and to also find out more about whatever youre interested and take advantage of wide base of knowledge around you.

The rest is here:
Student Cameron Kim, Working to Reprogram Cells

Donald Paul Lombardi, M.D. Joins The Oncology Institute of Hope and Innovation

The Oncology Institute of Hope and Innovation welcomes Dr. Donald Paul Lombardi.

Downey, California (PRWEB) October 08, 2012

He completed his internship and residency in Internal Medicine at the University of Michigan Hospitals, where he won the House Officer Research Award. He did his Medical Oncology Fellowship at the National Cancer Institute in Bethesda, MD, and did postgraduate fellowships in Molecular Genetics and Molecular Biology at the National Institutes of Health.

He was on the faculty at Washington University School of Medicine (then ranked #2 by the US News & World Report), where he specialized in breast and genitourinary cancers at the Siteman Cancer Center at Barnes-Jewish Hospital (then ranked #6 among US hospitals).

Because of his commitment to the cancer research, he enrolled into a Masters Degree Program in Clinical and Translational Investigation at the Kellogg School of Science at Technology at The Scripps Research Institute and Scripps Translational Science Institute in La Jolla, CA. Utilizing start-of-the-art genomics, proteomics and metabolomics, Dr. Lombardi focused his laboratory work on high fat diets and how they contribute to tumor aggressiveness. He will be coming from Scripps Cancer Center and Scripps Mercy Hospital.

Dr. Lombardi has received numerous honors and awards throughout his career, including a Physician-Scientist Training Award from the Department of Defense for U.S. Army Medical Research and Materiel Command's Breast Cancer Research Program; a Developmental Project/Career Development Award at the University of Texas SPORE in Lung Cancer; a Clinical Associate Physician (CAP) Award from the National Institutes of Health (NIH); and, most recently, a KL2 Clinical Scholarship from the NIH.

Dr. Lombardi has a very personal connection with cancer treatment. His mother, sister, and grandmother had breast cancer and his father had testicular cancer.

When I see a patient, I see the individual as a person with cancer first, and then as an oncologist treating that patient second. I think that I bring a passion to cancer care that comes from my own emotional response to having close family members go through cancer treatment.

Dr. Lombardi will be joining eleven other physicians on staff at The Oncology Institute of Hope and Innovation starting October 15th, 2012.

About The Oncology Institute:

Here is the original post:
Donald Paul Lombardi, M.D. Joins The Oncology Institute of Hope and Innovation

Four MU professors awarded Curators’ Professorships

Four MU professors were appointed as Curators Professors, the highest educational honor given by the UM System.

Statistics professor Nancy Flournoy, biochemistry professor Gerald Hazelbauer, fisheries and wildlife professor John Jones and geological sciences professor Mian Liu received the award after the UM Board of Curators approved the nominations at its September meeting.

The Curators Professorship is prestigious, and only outstanding scholars with established reputations are considered for appointment, according to the Office of the Provost's website.

The recipients were notified via mail by letters from Chancellor Brady Deaton, Provost Brian Foster and President Tim Wolfe about their nominations. In addition to the award, the recipients receive a raise and a stipend for scholarly activity.

Nancy Flournoy, statistics professor

Flournoy is the former statistics department chairwoman. She currently teaches one undergraduate class and one graduate class. Flournoy was the only woman of the four recognized.

It was really cool, Flournoy said. I was very pleased. Its a great honor.

Her work with statistical theory has been motivated by problems encountered while working with the Seattle bone marrow transplant team, according to her website. Flournoy received her bachelor's and master's degrees from the University of California, Los Angeles before receiving her Ph.D. from the University of Washington. Flournoy has spent 10 years at MU.

The students are a joy, Flournoy said.

Gerald Hazelbauer, biochemistry department chairman

Read more here:
Four MU professors awarded Curators’ Professorships

Nobel Prize in Physiology or Medicine 2012 awarded for discovery that mature cells can be reprogrammed to become …

ScienceDaily (Oct. 8, 2012) The Nobel Assembly at Karolinska Institutet has decided to award The Nobel Prize in Physiology or Medicine 2012 jointly to John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent.

The Nobel Prize recognizes two scientists who discovered that mature, specialised cells can be reprogrammed to become immature cells capable of developing into all tissues of the body. Their findings have revolutionised our understanding of how cells and organisms develop.

John B. Gurdon discovered in 1962 that the specialisation of cells is reversible. In a classic experiment, he replaced the immature cell nucleus in an egg cell of a frog with the nucleus from a mature intestinal cell. This modified egg cell developed into a normal tadpole. The DNA of the mature cell still had all the information needed to develop all cells in the frog.

Shinya Yamanaka discovered more than 40 years later, in 2006, how intact mature cells in mice could be reprogrammed to become immature stem cells. Surprisingly, by introducing only a few genes, he could reprogram mature cells to become pluripotent stem cells, i.e. immature cells that are able to develop into all types of cells in the body.

These groundbreaking discoveries have completely changed our view of the development and cellular specialisation. We now understand that the mature cell does not have to be confined forever to its specialised state. Textbooks have been rewritten and new research fields have been established. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy.

Life -- a journey towards increasing specialisation

All of us developed from fertilized egg cells. During the first days after conception, the embryo consists of immature cells, each of which is capable of developing into all the cell types that form the adult organism. Such cells are called pluripotent stem cells. With further development of the embryo, these cells give rise to nerve cells, muscle cells, liver cells and all other cell types -- each of them specialised to carry out a specific task in the adult body. This journey from immature to specialised cell was previously considered to be unidirectional. It was thought that the cell changes in such a way during maturation that it would no longer be possible for it to return to an immature, pluripotent stage.

Frogs jump backwards in development

John B. Gurdon challenged the dogma that the specialised cell is irreversibly committed to its fate. He hypothesised that its genome might still contain all the information needed to drive its development into all the different cell types of an organism. In 1962, he tested this hypothesis by replacing the cell nucleus of a frog's egg cell with a nucleus from a mature, specialised cell derived from the intestine of a tadpole. The egg developed into a fully functional, cloned tadpole and subsequent repeats of the experiment yielded adult frogs. The nucleus of the mature cell had not lost its capacity to drive development to a fully functional organism.

Gurdon's landmark discovery was initially met with scepticism but became accepted when it had been confirmed by other scientists. It initiated intense research and the technique was further developed, leading eventually to the cloning of mammals. Gurdon's research taught us that the nucleus of a mature, specialized cell can be returned to an immature, pluripotent state. But his experiment involved the removal of cell nuclei with pipettes followed by their introduction into other cells. Would it ever be possible to turn an intact cell back into a pluripotent stem cell?

Read more here:
Nobel Prize in Physiology or Medicine 2012 awarded for discovery that mature cells can be reprogrammed to become ...

UCSF Nobel Prize Winners

Shinya Yamanaka

Shinya Yamanaka, MD, PhD, is the fifth UCSF scientist to win the Nobel Prize in Physiology or Medicine.

Yamanaka is a busy man. He is a senior investigator and the L.K. Whittier Foundation Investigator in Stem Cell Biology at the Gladstone Institute of Cardiovascular Disease, a professor of anatomy at UCSF, director of the Center for iPS Cell Research and Application (CiRA) and a principal investigator at the Institute for Integrated Cell-Material Sciences (iCeMS), both at Kyoto University, Japan.

Other UCSF Nobel Prize winners include:

Elizabeth Blackburn

Elizabeth H. Blackburn, PhD, received the 2009 Nobel Prize in Physiology or Medicine. She shared the award with Carol W. Greider of Johns Hopkins University School of Medicine and Jack W. Szostak of Harvard Medical School. The scientists discovered an enzyme that plays a key role in normal cell function, as well as in cell aging and most cancers. The enzyme is called telomerase and it produces tiny units of DNA that seal off the ends of chromosomes, which contain the bodys genes. These DNA units named telomeres protect the integrity of the genes and maintain chromosomal stability and accurate cell division. They also determine the number of times a cell divides and thus determine the lifespan of cells.

The scientists research sparked a whole field of inquiry into the possibility that telomerase could be reactivated to treat such age-related diseases as blindness, cardiovascular disease and neurodegenerative diseases, and deactivated to treat cancer, in which it generally is overactive. Read more.

Stanley Prusiner

Stanley B. Prusiner, MD, received the 1997 Nobel Prize in Physiology or Medicine for his discovery of a novel disease-causing agent a protein he named prion (PREE-on). The prion causes rare neurodegenerative diseases, such as Creutzfeldt Jakob disease in humans, and mad cow disease in cattle. The discovery has informed research into the role of misprocessed proteins in more common brain diseases, including Alzheimers disease and Parkinsons disease.

J. Michael Bishop

The rest is here:
UCSF Nobel Prize Winners

Prize for medicine first to be announced

(CNN) -

The 2012 Nobel Prize for Physiology or Medicine was awarded Monday to Sir John B. Gurdon and Shinya Yamanaka for work that revolutionized the understanding of how cells and organisms develop.

The Nobel Assembly's announcement at the Karolinska Institute in Stockholm is the first for what will be a series of prizes announced this week. The Norwegian Nobel committee will announce the most anticipated of the annual honors -- the Nobel Peace Prize -- on Friday in Oslo.

Gurdon, 79, of Dippenhall, England, and Yamanaka, 50, of Osaka, Japan, share the prize jointly "for the discovery that mature cells can be reprogrammed to become pluripotent" -- the ability of a cell to differentiate into another cell type, according to the Nobel committee.

Gurdon discovered in 1962 that the cells are reversible in an experiment with an egg cell of a frog. Yamanaka discovered 40 years later that mature cells in mice could be reprogrammed as immature cells, the committee said.

"These groundbreaking discoveries have completely changed our view of the development and cellular specialisation. We now understand that the mature cell does not have to be confined forever to its specialised state," the Nobel Assembly said in a statement following the announcement.

"Textbooks have been rewritten and new research fields have been established. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy.

The prizes created in 1895 by Swedish industrialist Alfred Nobel honor work in physics, chemistry, literature and peace. Economics was added as a category in 1968, and the first prize awarded for economic sciences was in 1969.

The monetary award that accompanies the Nobel Prize was lowered by the foundation this year by 20% from 10 million Swedish kronor ($1.5 million) to 8 million kronor ($1.2 million) because of turbulence that hit the financial markets.

On Tuesday, the committee will announce its award for achievement in physics. The next day, the winner of the Nobel Prize in chemistry will be announced.

Go here to read the rest:
Prize for medicine first to be announced

The 2012 Nobel Prize in Physiology or Medicine

More Science Talk

Subscribe via iTunes

Showcasing more than fifty of the most provocative, original, and significant online essays from 2011, The Best Science Writing Online 2012 will change the way...

Read More

The Press Release from the Nobel Assembly at Karolinska Institute

The Nobel Prize in Physiology or Medicine 2012 goes jointly to John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent

Summary

The Nobel Prize recognizes two scientists who discovered that mature, specialised cells can be reprogrammed to become immature cells capable of developing into all tissues of the body. Their findings have revolutionised our understanding of how cells and organisms develop.

John B. Gurdon discovered in 1962 that the specialisation of cells is reversible. In a classic experiment, he replaced the immature cell nucleus in an egg cell of a frog with the nucleus from a mature intestinal cell. This modified egg cell developed into a normal tadpole. The DNA of the mature cell still had all the information needed to develop all cells in the frog.

Shinya Yamanaka discovered more than 40 years later, in 2006, how intact mature cells in mice could be reprogrammed to become immature stem cells. Surprisingly, by introducing only a few genes, he could reprogram mature cells to become pluripotent stem cells, i.e. immature cells that are able to develop into all types of cells in the body.

View post:
The 2012 Nobel Prize in Physiology or Medicine

Research and Markets: Digital Pathology Market – Slide Scanners, Analytics, Delivery Modes and Whole Slide Image …

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/4d2gld/digital_pathology) has announced the addition of the "Digital Pathology Market - Slide Scanners (Whole Slide Imaging), Analytics (Image Analysis Software), Delivery Modes (Web Based/ Cloud Based) and Whole Slide Image Storage - Global Trends & Forecast till 2017" report to their offering.

The life science industry is now witnessing the second decade of Biologic Revolution. The adoption and up gradation of technology is increasing rapidly. Conventional practices are being replaced by advanced technologies. The perception of pathological laboratories needs to be improved as the consumer expectations and government regulations towards improved patient safety, accurate diagnosis, Electronic Medical Records (EMR) as well as personalized medicines are growing. Pathology plays a significant role in patient care. Digital pathology serves this purpose by providing a facility for digital transformation of pathology and laboratory medicine.

Digital pathology is currently gaining momentum as pathologists are seeking to achieve workflow efficiency and cost cutting in the pathological process. It provides ready access to premium quality slide images, enabling better and fast diagnosis, as well as preservation of these digital slides for future reference. The digital pathology market is driven by the factors such as reduction in laboratory expenses, improvement in operational efficiency, and treatment decisions and patient care. The rising prevalence of cancer, increasing trends in drug development, companion diagnostics, and ease of consultation are the major drivers that are slated to propel this market. However, a few pivotal factors restraining the growth of this market are FDA regulations in some regions, high cost of Digital Pathology Systems (DPS), technological problems, and conservative outlook of pathologists. There are a few well-established firms and several small ones operating in this industry. The major players in the market are Aperio Technologies, Inc. (U.S.), Ventana Medical Systems (U.S.), Leica Microsystems GmbH (Germany), Digipath (U.S.), and Hamamatsu Photonics (Japan).

The global digital pathology market is broadly segmented into two categories based on its products and application. The product category includes scanners, analytics (visualization software, information management systems and image analysis platforms), storage and communication (sharing services, software), while the application category comprises human pathology and animal pathology. Both these markets are dominated by North America in 2012, followed by Europe, Asia, and Rest of the World (RoW). The global digital pathology market is estimated to be $191.00 million in 2012, and is poised to grow at a CAGR of 12% to reach $336.61 million by 2017.

Key Topics Covered:

1 Introduction

2 Executive Summary

3 Market Overview

4 Digital Pathology: Rationale For Adoption

Read the original here:
Research and Markets: Digital Pathology Market - Slide Scanners, Analytics, Delivery Modes and Whole Slide Image ...

DNA Sequencing Market Growth Driven by Top 10 Companies and Technologies

ReportsnReports.com adds new market research report Top Ten Companies in DNA Sequencing to its store. Global sequencing products market is forecast to reach $6.6 billion by 2016.

Dallas, Texas (PRWEB) October 08, 2012

The goal of this report is to provide a more in-depth look at the top tier DNA sequencing companies as well as some of the second tier companies to look for in the near future, and to note the technological changes within the DNA sequencing industry that are sure to play a role in the years to come.

More specifically, the objectives include identifying companies that are considered the leaders in their field and the technological means these companies are using to exploit their markets and dominate their field.

Key technology points explored include:

Other major factors used to determine top companies in the field include:

INTENDED AUDIENCE

This study will be of particular interest to life-science research tools suppliers, pharmaceutical, diagnostics, nanotechnology, bioinformatics, semiconductor, and biotechnology companies. It will also be valuable to companies involved in genome sequencing projects, sequencing centers, manufacturers of microarrays, suppliers of molecular diagnostics assays, bioinformatics companies, and cancer researchers and clinicians. As this report is a profiling of top companies in the DNA sequencing field, the main audience should also include executive management personnel and marketing and financial analysts.

SCOPE

The scope of this report is focused on a select 10 companies in DNA sequencing, and the key areas in the field that are driving industry growth allowing these companies to succeed. These areas include Sanger, next-generation, and emerging sequencing technologies; the markets for sample preparation products, sequencing instruments and consumables; and bioinformatics and sequencing services. A key area BCC also explores is industry structure, noting strategic alliances and acquisitions along with pertinent patent information.

Follow this link:
DNA Sequencing Market Growth Driven by Top 10 Companies and Technologies

Posted in DNA

Forensic Anthropologist Uses DNA to Solve Real-Life Murder Mysteries in Latin America

"Seora, go and search for yourself." With those words, Mexican authorities sent away the grieving mother seeking clues about her daughter's killer. The year was 2001, after those authorities had discovered the bodies of eight young women in a cotton field near Ciudad Jurez on the Texas-Mexico border, across the Rio Grande from the U.S. city of El Paso. Police were unlikely to solve their cases, just like those of the hundreds of women who had been sexually abused, mutilated and killed in this lawless town, where this year alone another 60 women and girls have been murdered. The government's handling of the "Campo Algodonero" murders stood out as an egregious violation of human rights for the way the authorities botched the case and mishandled the women's remains.

The victims' mothers even came to doubt that the remains authorities had given them were their own children. In December 2003 they began working with Mercedes Doretti, a New York-based forensic anthropologist and co-founder of the Argentine Forensic Anthropology Team to get help in identifying the bodies.

Doretti's work in Ciudad Jurez revealed that law enforcement had misidentified three of the eight remains furnished, and her report to the Inter-American Court of Human Rights led in 2009 to an order for reparations to all the families and a condemnation of the Mexican justice system. That small victory cemented Doretti's resolve to probe deeper. She now knew that dozens of other bodies had no possible matches to local families. Where had these other victims come from?

Doretti, a stylish woman in her 50s, has spent her life supporting human rights. She studied anthropology in Buenos Aires, during the height of Argentina's "Dirty War," when the right-wing regime kidnapped, tortured and murdered some 20,000 students, activists, journalists and guerrillas. Her team's work identifying remains of the Desaparecidosthe disappeared onescontinues today, and evidence she personally collected in the 1980s is still making its way through the country's legal system. In 2007 the MacArthur Foundation awarded her a "genius grant" for her work investigating human rights abuses around the world, and she serves as a Chairman of the Board of Trustees of the United Nations Voluntary Fund for Victims of Torture.

Doretti suspected that some of the unidentified bodies in Mexico may have been migrants journeying north from Central America, and in 2009 she established the Missing Migrants project. The full scope of the problem is hard to pin down, but some 200 migrants die of exposure each summer in southern Arizona alone. Mexico's criminal gangs have kidnapped many more for extortion or murdered and buried these victims in mass graves. Doretti has created a network of forensic DNA banks in El Salvador, Honduras and Chiapas, Mexico and recently announced her first positive identifications from remains recovered in Texas and Arizona. "It's amazing what she's doing," says Bruce Anderson, forensic anthropologist with the medical examiner's office in Pima County, Arizona.

Scientific American met Doretti at her organization's spartan one-room office in Brooklyn's DUMBO neighborhood. Edited excerpts follow.

When the Argentinean dictatorship collapsed in 1982, you still thought that you might follow an academic anthropology path. How did you get introduced to forensics? I was at a demonstration against the International Monetary Fund in January 1984, and one of my friends came and said: "There's a gringo who wants to exhume disappeared people." As it happened, the American Association for the Advancement of Science had sent a scientist named Clyde Snow down to train people in forensics, but the Argentinean Anthropology Association initially did not want to get involved directly. Snow didn't have anybody to work with. Frankly, it sounded very strange to me. But after meeting him the next day, I realized everything he was saying made total senseto apply the techniques of traditional archaeology and biological anthropology into the forensic field so that we will be able to recover and identify the remains of Los Desaparecidos in the proper way.

Were you afraid of the consequences of working on a politically charged project like this? I was very scared. If you look at the history of Argentina, there had been a coup of every democratic government since the 1930s. If there was another coup we knew we would probably have to leave the country. Also, none of us knew how we were going to react personally when entering a cemetery. It's very different to dig up remains 10,000 years old than to dig up recent remains. We would also be working surrounded by the police, who brought back terrible memories from the dictatorship.

Was your family affected by the dictatorship? Yes, though not in the way in which other families were affected. We didn't lose any members of our family, but because my mother worked as a journalist and was talking about these things on her daily radio show, she was constantly receiving death threats. We thought about leaving the country.

Several days after meeting Snow, you began your work at a cemetery as part of a judicial investigation. What was the condition of the first remains you uncovered? They were fully skeletonized and, to my surprise, I was able to cope. I was very concentrated on the details of digging and cleaning the skull and making sure that the teeth didn't fall out and things like that.

Read the original:
Forensic Anthropologist Uses DNA to Solve Real-Life Murder Mysteries in Latin America

Posted in DNA

A novel oncogenic network specific to liver cancer initiation

ScienceDaily (Oct. 7, 2012) Researchers headed by Erwin Wagner, the Director of the BBVA Foundation-CNIO Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), have deciphered how a stress-inducible gene regulator, AP-1, controls the survival of liver tumor-initiating cells. These results, published in the online edition of Nature Cell Biology, could provide new preventive strategies and identify potentially targetable molecules to prevent liver cancer.

Hepatocellular carcinoma (HCC) causes more than 500,000 deaths per year worldwide. While patients with chronic hepatitis virus B and C infections or liver cirrhosis are high-risk populations for HCC, measures aiming at preventing HCC development in these patients are limited. In addition, the long-term prognosis after surgical resection of HCC remains poor, due to the high rate of de novo recurrence and the lack of effective preventive therapy.

The critical step for developing effective preventive therapies, but also diagnostic markers and preventive strategies is to identify targetable molecules and pathways responsible for cancer initiation.

Using genetic mouse models specific for liver cancer initiation, researchers have discovered how the stress-inducible AP-1 gene regulator modulates liver tumor cell death in early stages of liver cancer. Mechanistically, AP-1 controls the expression of the epigenetic modulator SIRT6. Subsequently, SIRT6 represses Survivin, which is involved in programmed cell death.

Importantly, altering these proteins in mice even transiently during the initiation stage markedly impaired liver cancer development in mice.

The relevance of these findings was tested in more than 150 human tissue samples collected in patients from Asia and Europe. A clear correlation between these proteins and liver cancer initiation, but not in advanced HCCs, was observed.

These results connect liver cancer initiation with epigenetics and cell death, and give new insights into why patients with metabolic diseases where SIRT6 is important, are at risk of developing of liver cancer.

"Our study provides not only novel implications for the development of preventive therapies for high risk cirrhotic or post-resection patients, but also a new paradigm how one can molecularly dissect cancer initiation using mouse models in combination with the appropriate human samples," states Latifa Bakiri, author of the study.

The study was initiated in Erwin Wagners group at the IMP in Vienna and subsequently carried out at the Spanish National Cancer Research Centre (CNIO) and at the State Key Laboratory of Cell Biology, in Shanghai China led by Lijian Hui.

The study also involves the participation of clinical researchers at Fudan University in Shanghai and the Medical University of Graz, Austria.

More:
A novel oncogenic network specific to liver cancer initiation

Omicron has Chemistry

SOUTH BEND -- Anthony Serianni was a postdoctoral associate at Cornell University when he and his adviser, Robert Barker, started Omicron Biochemicals in 1982, the same year Serianni joined the faculty at the University of Notre Dame.

"We had developed some new chemistry that made the synthesis of certain kinds of sugar molecules easier to do," says Serianni, the president and CEO. "At that time, I had intentions of pursuing an academic career. I had already applied to Notre Dame.

"We are a carbohydrate lab, a sugar lab," adds Serianni, a professor of chemistry and biochemistry and a fellow of the American Association for the Advancement of Science. "There's an explosion in the interest in carbohydrates in biology, not just for dietary reasons."

Sugar molecules coat many cells in the human body and interact with other material such as bacteria, viruses and proteins, potentially offering targets for fighting disease, he explains.

"There are lots of molecules that attach themselves to the cell because of the sugars," he says. "Those interactions elicit a whole host of biological responses. Some people believe cancer can be treated by pharmacological intervention on saccharide."

Omicron is not a research laboratory but synthesizes material used in other laboratories.

"We provide the tools, that is, the molecules, that are needed for studies of that type," Serianni says. "When we build these molecules in that lab, we label them. The nuclei of the atoms that compose these molecules are tinkered with slightly," a process called isotopic labeling. "That type of labeling is really valuable."

In some cases, quantities ordered have increased dramatically since the beginning.

"Years ago, a large-scale synthesis of these products might have been 1 to 5 grams," he says, adding that some orders are for thousands of grams. "On the other hand, many of these products are custom-made. They're difficult syntheses. Having a gram or two of material, you're doing pretty well. It varies by the product.

"The need for these kinds of molecules is pretty broad. Lots of different kinds of laboratories doing chemical and biological research might need them."

Original post:
Omicron has Chemistry

Be younger now

Today is the moment. And now is the time to take action. The population of the world is aging at a rapid rate. And according to a 2011 research paper from the Harvard School of Public Health, there will be close to a billion people over the age of 60 by 2020, doubling to nearly two billion by 2050.

This staggering number represents 22 percent of the worlds population. And it can only translate to one realitythat the business of anti-aging (or aging, for that matter) is a serious one.

A report by the MIT Age Lab reveals that the 50 and above age group represents the fastest-growing segment worldwide.

This new phenomenon has catapulted the wellness industry to a booming global business. In a report by the Global Spa Summit, it was stated that the beauty and anti-aging segment of the wellness industry was valued at $679.1 billion in 2012. And its still growing.

Nothing instant

With the growing demand for treatments to delay aging, there has been an unprecedented spike in the clamor for the quick fix. Instant is the operative word. And suddenly mushrooming are spas, beauty centers, and even beauty parlors offering procedures that may be questionable and often risky.

We have known of many instances where patients have been disfigured or lost their lives due to excessive treatments promising quick transformations. Apart from the risks, all anti-aging treatments are expensive and not within the reach of the average individual.

Truth be told, recapturing ones youth isnt a matter of popping super pills, sophisticated regimens, injections or surgery. The most effective anti-aging regimen is good health. While this is not meant to disparage conventional medicine which can offer effective ways to address health and beauty challenges, it has long been observed by health experts that the quality of ones life offers a longer-lasting effect on ones overall well-being and personal good looks.

Working with nature

This scenario seems all too familiar.

Read more:
Be younger now

California initiative to test appetite for ‘genetically engineered’ food

The Associated Press Published Sunday, Oct. 7, 2012 10:03AM EDT

LOS ANGELES -- Calories. Nutrients. Serving size. How about "produced with genetic engineering?"

California voters will soon decide whether to require certain raw and processed foods to carry such a label.

In a closely watched test of consumers' appetite for genetically modified foods, the special label is being pushed by organic farmers and advocates who are concerned about what people eat even though the federal government and many scientists contend such foods are safe.

More than just food packaging is at stake. The outcome could reverberate through American agriculture, which has long tinkered with the genes of plants to reduce disease, ward off insects and boost the food supply.

International food and chemical conglomerates, including Monsanto Co. and DuPont Co., have contributed about $35 million to defeat Proposition 37 on the November ballot. It also would ban labeling or advertising genetically altered food as "natural." Its supporters have raised just about one-tenth of that amount.

If voters approve the initiative, California would become the first state to require disclosure of a broad range of foods containing genetically modified organisms, or GMOs. Food makers would have to add a label or reformulate their products to avoid it. Supermarkets would be charged with making sure their shelves are stocked with correctly labeled items.

Genetically altered plants grown from seeds engineered in the laboratory have been a mainstay for more than a decade. Much of the corn, soybean, sugar beets and cotton cultivated in the United States today have been tweaked to resist pesticides or insects. Most of the biotech crops are used for animal feed or as ingredients in processed foods including cookies, cereal, potato chips and salad dressing.

Proponents say explicit labeling gives consumers information about how a product is made and allows them to decide whether to choose foods with genetically modified ingredients.

"They're fed up. They want to know what's in their food," said Stacy Malkan, spokeswoman for the California Right to Know campaign.

See the rest here:
California initiative to test appetite for 'genetically engineered' food

Huron Technologies Awarded 1st Prize in Fluorescence Scanning Contest

October 3, 2012 Waterloo, ON – Huron Technologies International Inc., recently was awarded 1st prize in two categories at the 2nd International Scanner Contest (ISC) held in Berlin, Germany and announced in Prague, Czech Republic, at the European Congress of...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/i57tHcxkN8A/huron-technologies-awarded-1st-prize-in-fluorescence-scanning-contest.html

Meet A Pioneer in Digital Pathology and Virtual Microscopy

Meet A Pioneer in Digital Pathology and Virtual Microscopy: Dr. Béla Molnár, Semmelweis University & 3DHISTECH Dr. Béla Molnár is an award-winning Physician at Semmelweis University’s 2nd Department of Internal Medicine in Hungary, where he specializes in gastroenterology and colorectal...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/rEj6KgeNYCg/meet-a-pioneer-in-digital-pathology-and-virtual-microscopy.html

Definiens closes €10 Million Round to Grow its Clinical Digital Pathology Business

Investments into the clinical digital pathology space continue to be made. Recent news of Definiens private funding, expanding on their portfolio and experience in research and development and pharmaceutical shows increasing interest in the clinical market. Good news for healthcare...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/9rm_AjGl7kc/definiens-closes-10-million-round-to-grow-its-clinical-digital-pathology-business.html

MarketsandMarkets: Global Digital Pathology Market Worth $336.6 Million by 2017

MarketsandMarkets: Global Digital Pathology Market Worth $336.6 Million by 2017 (via PR Newswire) The market size mentioned here comes in less (multi-billion dollar size) than was previously mentioned here, here, here, here and here. No way for me to know...

Source:
http://feedproxy.google.com/~r/DigitalPathologyBlog/~3/pl7kyd7N-QY/marketsandmarkets-global-digital-pathology-market-worth-3366-million-by-2017.html